Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

EACR 2012 /
Australia Pancreatic Cancer Genome Initiative

7th - 10th Jul 2012

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 18.07.12
Views: 4464
Rating:

Dr Marina Pajic – The Garvan Institute of Medical Research, Darlinghurst, Australia

As part of the International Cancer Genome Consortium, the Australia Pancreatic Cancer Genome Initiative (APGI) is working to develop personalised medicines for pancreatic cancer patients.

Dr Marine Pajic discusses her work carrying out preclinical studies to validate new agents proposed for personalised pancreatic cancer treatments.

Thanks to the positive results of these studies using patient DNA and RNA to identify treatment targets, the APGI is expecting to launch the IMPACT trial of personalised medicines at the end of the year.

Previous conferences: highlights



Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation